InMed Pharmaceuticals

InMed Pharmaceuticals Current Liabilities

The Current Liabilities of InMed Pharmaceuticals (INM) as of Nov 3, 2026 is 1.84 M USD. In the previous year, Current Liabilities was 1.97 M USD — a change of -6.70% (lower).

Current Liabilities

1.84 MUSD

YoY

-6.70%

Last updated:

Current Liabilities of InMed Pharmaceuticals is 2025 1.84 M USD. Current Liabilities of InMed Pharmaceuticals was 2024 1.97 M USD. It decreases by -6.70% lower compared to the previous year.

The InMed Pharmaceuticals Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2018
710,000.00 USD
Jan 1, 2019
1.19 M USD
Jan 1, 2020
1.68 M USD
Jan 1, 2021
2.21 M USD
Jan 1, 2022
3.32 M USD
Jan 1, 2023
2.00 M USD
Jan 1, 2024
1.97 M USD
Jan 1, 2025
1.84 M USD
The InMed Pharmaceuticals Current Liabilities history
YEARCurrent LiabilitiesYoY
1.84 MUSD-6.70%
1.97 MUSD-1.41%
2.00 MUSD-39.76%
3.32 MUSD+50.23%
2.21 MUSD+31.55%
1.68 MUSD+41.18%
1.19 MUSD+67.61%
710,000.00USD+144.83%
290,000.00USD-36.96%
460,000.00USD+666.67%
60,000.00USD-14.29%
70,000.00USD+40.00%
50,000.00USD0.00%
50,000.00USD0.00%
50,000.00USD-96.06%
1.27 MUSD+20.95%
1.05 MUSD-29.53%
1.49 MUSD+13.74%
1.31 MUSD+19.09%
1.10 MUSD-29.03%
1.55 MUSD+106.67%
750,000.00USD+56.25%
480,000.00USD+585.71%
70,000.00USD-86.00%
500,000.00USD-55.75%
1.13 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

InMed Pharmaceuticals Stock analysis

What does InMed Pharmaceuticals do? InMed Pharmaceuticals Inc is a biopharmaceutical company based in Vancouver, Canada, listed on the stock exchange in June 2001. The firm operates through two main segments: InMed Pharmaceuticals and BayMedica. The InMed segment focuses on the research and development of prescription-based cannabinoid products, specifically targeting diseases with high unmet medical needs. Key candidates include INM-755, a topical skin cream for Epidermolysis Bullosa, and INM-088 for glaucoma treatment. The BayMedica segment develops proprietary manufacturing technologies to produce rare cannabinoids for the health and wellness industry. The company leverages its expertise in rare cannabinoids and analogs to address significant therapeutic gaps. InMed Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about InMed Pharmaceuticals stock

Current Liabilities of InMed Pharmaceuticals is 1.84 M USD in 2025.

Current Liabilities of InMed Pharmaceuticals changed from 1.97 M USD to 1.84 M USD, representing a -6.70% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities InMed Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's InMed Pharmaceuticals historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — InMed Pharmaceuticals

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — InMed Pharmaceuticals